Clinical Trial Detail

NCT ID NCT02543645
Title A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celldex Therapeutics
Indications

urinary bladder cancer

head and neck cancer

triple-receptor negative breast cancer

renal cell carcinoma

lung non-small cell carcinoma

melanoma

Therapies

Atezolizumab + Varlilumab

Age Groups: adult

No variant requirements are available.